These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29982712)

  • 21. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
    Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
    J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Sjogren's syndrome: current and prospective therapies.
    Thanou-Stavraki A; James JA
    Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.
    Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S
    Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome.
    James K; Chipeta C; Parker A; Harding S; Cockell SJ; Gillespie CS; Hallinan J; Barone F; Bowman SJ; Ng WF; Fisher BA;
    Rheumatology (Oxford); 2018 Jul; 57(7):1222-1227. PubMed ID: 29608774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of diagnosis and disease course in primary Sjögren's syndrome: Results from datamining of electronic health records.
    Sandhya P; Janardana R; Sudarsanam T; Mahasampath G; Prakash JAJ; Danda D
    Int J Rheum Dis; 2019 Sep; 22(9):1768-1774. PubMed ID: 31328441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.
    Wise LM; Arkfeld DG
    Clin Rheumatol; 2020 Apr; 39(4):1357-1362. PubMed ID: 31863212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome.
    Liu Y; Liao X; Wang Y; Chen S; Sun Y; Lin Q; Shi G
    Oncotarget; 2017 Feb; 8(9):14306-14313. PubMed ID: 28147328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting lymphoma development in patients with Sjögren's syndrome.
    De Vita S; Gandolfo S
    Expert Rev Clin Immunol; 2019 Sep; 15(9):929-938. PubMed ID: 31347413
    [No Abstract]   [Full Text] [Related]  

  • 30. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome.
    Verstappen GM; Meiners PM; Corneth OBJ; Visser A; Arends S; Abdulahad WH; Hendriks RW; Vissink A; Kroese FGM; Bootsma H
    Arthritis Rheumatol; 2017 Sep; 69(9):1850-1861. PubMed ID: 28564491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging drugs for primary Sjögren's syndrome.
    Gandolfo S; De Vita S
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):121-132. PubMed ID: 31286787
    [No Abstract]   [Full Text] [Related]  

  • 34. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Seror R; Pers JO; Meiners PM; Vissink A; Bootsma H; Nowak E; Saraux A
    Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.
    Draborg AH; Lydolph MC; Westergaard M; Olesen Larsen S; Nielsen CT; Duus K; Jacobsen S; Houen G
    PLoS One; 2015; 10(9):e0138753. PubMed ID: 26402865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
    Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S;
    BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome.
    Nishikawa A; Suzuki K; Kassai Y; Gotou Y; Takiguchi M; Miyazaki T; Yoshimoto K; Yasuoka H; Yamaoka K; Morita R; Yoshimura A; Takeuchi T
    Arthritis Res Ther; 2016 May; 18(1):106. PubMed ID: 27180164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperviscosity in primary Sjögren's syndrome: clinical implications.
    Hernández-Molina G; Bermúdez-Bermejo P
    Int J Rheum Dis; 2017 Jan; 20(1):84-89. PubMed ID: 26807556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
    Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
    Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome.
    Moerman RV; Arends S; Meiners PM; Vissink A; Spijkervet FK; Kroese FG; Brouwer E; Bootsma H
    J Rheumatol; 2017 Mar; 44(3):292-296. PubMed ID: 28089983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.